Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: No long-term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group

Abstract

No late cardiac damage was demonstrated in childhood ALL survivors after induction treatment including a cumulative dose of 100 mg/m(2) DNR, compared to survivors who received the same treatment but without DNR. DNR 100 mg/m(2) given in 4 doses of 25 mg/m(2)/week appears to be a safe dose in induction treatment of ALL.